Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.68 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.66 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.66 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.66 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.66 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.66 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024223 | 1.00 | CXCR2 (0.68) | CXCR2CXCR1MEN1KMT2APABPC1 | |
| SCHEMBL915213 | 0.85 | MEN1 (0.64) | CXCR2CXCR1MEN1KMT2APABPC1 | |
| SCHEMBL4320209 | 0.83 | HTT (0.68) | MEN1KMT2ACTDSP1MAPTALDH1A1 | |
| SCHEMBL4320215 | 0.83 | HTT (0.68) | MEN1KMT2ACTDSP1MAPTALDH1A1 | |
| SCHEMBL9311420 | 0.82 | CXCR2 (0.59) | CXCR2CXCR1MEN1KMT2APABPC1 | |
| SCHEMBL11874002 | 0.82 | CXCR1 (0.68) | CXCR2CXCR1MEN1KMT2APABPC1 | |
| SCHEMBL5595042 | 0.82 | CXCR2 (1.00) | CXCR2CXCR1MEN1KMT2APABPC1 | |
| SCHEMBL2852168 | 0.81 | KMT2A (0.69) | MEN1KMT2ARAB9AMAPTGAA | |
| SCHEMBL2230525 | 0.81 | KMT2A (0.52) | CXCR2CXCR1MEN1KMT2APABPC1 | |
| SCHEMBL2230530 | 0.81 | KMT2A (0.52) | CXCR2CXCR1MEN1KMT2APABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-04-06 | — | — | US | disclosed |
| US-9549927-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9415049-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150374690-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2015-12-31 | — | — | US | disclosed |
| EP-2935226-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9126950-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014100748-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179720-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CXCR2 1254/4885CXCR1 1279/4885MEN1 1321/4885 |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | CXCR2 858/4885CXCR1 3426/4885MEN1 2025/4885 |
| US-20150374690-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CXCR2 449/4885CXCR1 2143/4885MEN1 606/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | CXCR2 858/4885CXCR1 3426/4885MEN1 2025/4885 |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CXCR2 449/4885CXCR1 2143/4885MEN1 606/4885 |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CXCR2 449/4885CXCR1 2143/4885MEN1 606/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | CXCR2 858/4885CXCR1 3426/4885MEN1 2025/4885 |
| US-20140179720-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CXCR2 449/4885CXCR1 2143/4885MEN1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.